PMID- 31476693
OWN - NLM
STAT- MEDLINE
DCOM- 20200303
LR  - 20200303
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 76
DP  - 2019 Nov
TI  - Eupatilin attenuates the inflammatory response induced by intracerebral 
      hemorrhage through the TLR4/MyD88 pathway.
PG  - 105837
LID - S1567-5769(19)31447-X [pii]
LID - 10.1016/j.intimp.2019.105837 [doi]
AB  - BACKGROUND: Intracranial hemorrhage (ICH) is one of the most common brain 
      traumas, and inflammation caused by ICH seriously affects the quality of life and 
      prognosis of patients. Eupatilin has been shown to have anti-inflammatory effects 
      in various diseases. However, only one paper has reported that Eupatilin has a 
      therapeutic effect on the inflammatory response caused by ICH and the underlying 
      mechanism needs to be studied. METHODS: We used erythrocyte lysis stimulation 
      (ELS) to induce mouse microglia BV2 as the inflammation model. CCK-8 and 
      Transwell assays were used to detect cell viability and migration. RT-PCR, 
      western blotting, and ELISA were used to detect the secretion of inflammatory 
      factors and the expression of related mechanism proteins. HE staining was used to 
      detect cell edema and death. RESULT: We found that ELS significantly increased 
      protein and mRNA levels and secretion of inflammatory factors IL-1beta and TNF-alpha, 
      which Eupatilin attenuated through the Toll-like receptor 4 (TLR4)/myeloid 
      differentiation factor 88 (MyD88) pathway. The anti-inflammatory effect of 
      Eupatilin was significantly attenuated after siRNA was used to reduce TLR4 
      expression. The experimental results and mechanism were also verified in TLR4 
      knockout mice in vivo. CONCLUSION: Eupatilin has a therapeutic effect on 
      inflammation caused by ICH. The underlying mechanism may be related to 
      TLR4/MyD88, which brings new hope for clinical patients to improve symptoms and 
      prognosis.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Fei, Xiaowei
AU  - Fei X
AD  - Department of Neurosurgery, Sichuan Academy of Medical Sciences, Sichuan 
      Provincial People's Hospital, School of Medicine University of Electronic Science 
      and Technology of China, Chengdu 610072, China.; Dapartment of Physiology, Dalian 
      Medical University, Dalian 116044, China.; Institute of Neurosurgery, Affiliated 
      Bayi Brain Hospital, General Army Hospital, Beijing 10000, China.
FAU - Chen, Chen
AU  - Chen C
AD  - Institute of Neurosurgery, Affiliated Bayi Brain Hospital, General Army Hospital, 
      Beijing 10000, China.
FAU - Kai, Sun
AU  - Kai S
AD  - Institute of Neurosurgery, Affiliated Bayi Brain Hospital, General Army Hospital, 
      Beijing 10000, China.
FAU - Fu, Xiaojun
AU  - Fu X
AD  - Institute of Neurosurgery, Affiliated Bayi Brain Hospital, General Army Hospital, 
      Beijing 10000, China.
FAU - Man, Weitao
AU  - Man W
AD  - Department of Neurosurgery, Beijing Tsinghua Changgung Hospital, School of 
      Clinical Medicine, Tsinghua University, Beijing 102218, China.
FAU - Ding, Boyun
AU  - Ding B
AD  - Institute of Neurosurgery, Affiliated Bayi Brain Hospital, General Army Hospital, 
      Beijing 10000, China.
FAU - Wang, Chongwu
AU  - Wang C
AD  - Institute of Neurosurgery, Affiliated Bayi Brain Hospital, General Army Hospital, 
      Beijing 10000, China.. Electronic address: darklordwcw@163.com.
FAU - Xu, Ruxiang
AU  - Xu R
AD  - Department of Neurosurgery, Sichuan Academy of Medical Sciences, Sichuan 
      Provincial People's Hospital, School of Medicine University of Electronic Science 
      and Technology of China, Chengdu 610072, China.; Institute of Neurosurgery, 
      Affiliated Bayi Brain Hospital, General Army Hospital, Beijing 10000, China.. 
      Electronic address: 524727684@qq.com.
LA  - eng
PT  - Journal Article
DEP - 20190830
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Flavonoids)
RN  - 0 (IL1B protein, mouse)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Myd88 protein, mouse)
RN  - 0 (Myeloid Differentiation Factor 88)
RN  - 0 (Tlr4 protein, mouse)
RN  - 0 (Tnf protein, mouse)
RN  - 0 (Toll-Like Receptor 4)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 4D58O05490 (eupatilin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - Cell Line
MH  - Cell Movement/drug effects
MH  - Cell Survival/drug effects
MH  - Cerebral Hemorrhage/*drug therapy/genetics/immunology
MH  - Flavonoids/pharmacology/*therapeutic use
MH  - Interleukin-1beta/genetics/immunology
MH  - Mice, Knockout
MH  - Microglia/drug effects/physiology
MH  - Myeloid Differentiation Factor 88/genetics/immunology
MH  - Signal Transduction/drug effects
MH  - Toll-Like Receptor 4/genetics/immunology
MH  - Tumor Necrosis Factor-alpha/genetics/immunology
OTO - NOTNLM
OT  - Eupatilin
OT  - IL-1beta
OT  - Inflammation
OT  - Intracranial hemorrhage
OT  - TLR4
OT  - TNF-alpha
EDAT- 2019/09/03 06:00
MHDA- 2020/03/04 06:00
CRDT- 2019/09/03 06:00
PHST- 2019/07/03 00:00 [received]
PHST- 2019/08/09 00:00 [revised]
PHST- 2019/08/18 00:00 [accepted]
PHST- 2019/09/03 06:00 [pubmed]
PHST- 2020/03/04 06:00 [medline]
PHST- 2019/09/03 06:00 [entrez]
AID - S1567-5769(19)31447-X [pii]
AID - 10.1016/j.intimp.2019.105837 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2019 Nov;76:105837. doi: 10.1016/j.intimp.2019.105837. Epub 
      2019 Aug 30.